Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9P0K9
UPID:
FRS1L_HUMAN
Alternative names:
Brain protein CG-6; Ferric-chelate reductase 1-like protein
Alternative UPACC:
Q9P0K9; Q5T4G4
Background:
DOMON domain-containing protein FRRS1L, also known as Brain protein CG-6 and Ferric-chelate reductase 1-like protein, plays a crucial role in the glutamate signaling pathway. This pathway is essential for normal brain function, influencing neurodevelopment and neuronal communication.
Therapeutic significance:
The protein is linked to Developmental and epileptic encephalopathy 37 (DEE37), a severe early-onset epilepsy with neurodevelopmental impairment. Understanding the role of DOMON domain-containing protein FRRS1L could open doors to potential therapeutic strategies for DEE37 and related neurological disorders.